Medical Therapies for Pediatric Lymphatic Malformations: A Systematic Review
Open Access
- 31 October 2025
- journal article
- review article
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (3) , 259-264
Abstract
Introduction: Lymphatic malformations (LM) are vascular anomalies that can be challenging to manage with new medical therapies emerging. This systematic review examines current medical therapies for pediatric patients with LMs that involve the soft tissues. Materials and Methods: MEDLINE, Embase, Cochrane Library, and SCOPUS were searched on April 12, 2024, using variations of the keywords “lymphatic malformation” AND “drug therapy” AND “pediatric.” Language was limited to English, and no date restriction was applied. Treatment success was defined as a reduction in lesion size of over 10%, with complete response (CR) defined as a reduction in size of over 90%. Results: Our review encompassed 4937 title/abstracts, 436 full-texts and ultimately included 77 studies. Reported success rates were variable, with notable results for alpelisib (oral) (n = 9/9), sirolimus (oral) (n = 257/287), sirolimus (topical) (n = 13/15), acetylsalicylic acid (oral) (n = 18/23), propranolol (oral) (n = 19/29), and sildenafil (oral) (n = 33/71). CR was reported with isotretinoin (n/a) (n = 1/1), cyclophosphamide (iv) (n = 1/2), acetylsalicylic acid (oral) (n = 4/23), sirolimus (topical) (n = 2/15), and sirolimus (oral) (n = 17/287). Conclusion: Overall, therapies such as alpelisib and sirolimus showed promising results in the reduction of pediatric LM size; however, additional long-term data are needed to validate their efficacy and safety profile. Limitations of our study include heterogeneity and a potential risk of bias.Keywords
This publication has 36 references indexed in Scilit:
- Differences in Efficacy and Safety of Sirolimus and Sildenafil in Pediatric Lymphatic MalformationsThe Laryngoscope, 2023
- Sirolimus (Rapamycin) for Slow-Flow Malformations in ChildrenJAMA Dermatology, 2021
- Acetylsalicylic acid suppression of the PI3K pathway as a novel medical therapy for head and neck lymphatic malformationsInternational Journal of Pediatric Otorhinolaryngology, 2021
- Fetal therapy using rapamycin for a rapidly enlarging, obstructive, cervical lymphatic malformation: a case reportPrenatal Diagnosis, 2021
- Treatment of a tongue lymphangioma with sirolimus after failure of surgical resection and propranololPediatric Blood & Cancer, 2013
- Somatic Mosaic Activating Mutations in PIK3CA Cause CLOVES SyndromeThe American Journal of Human Genetics, 2012
- Pathogenesis of lymphangiomasVirchows Archiv, 2008
- Rapamycin and mTOR kinase inhibitorsJournal of Chemical Biology, 2008
- Safety and efficacy of Sildenafil therapy in children with pulmonary hypertensionInternational Journal of Cardiology, 2005
- Cyclophosphamide therapy in life-threatening inoperable cystic hygromasPediatric Surgery International, 1995